Relevant clinical and pathologic features of t(11;14)–negative MCL cases
| Case no. . | Sex . | Age, y . | Ann Arbor stage . | Extranodal sites . | Initial therapy . | Response . | Follow-up, mo/status . | Pathologic features . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marker expression . | Growth pattern/cytology . | ||||||||||||||
| Cyclin . | p27 . | RB1 . | Other reviewed markers . | ||||||||||||
| CD3 . | CD5 . | CD10 . | CD20 . | ||||||||||||
| 1 | F | 43 | IVB | BM, T | CHVmP-BV, CEP, DHAP | PR | 19/D | D1 | +w | + | — | +w | — | + | Vagualy nodular/typical |
| 2 | M | 51 | IVB | BM, S, CNS | CHVmP-BV | PR | 64/D | D1 | + | + | — | + | — | + | Nodular/typical |
| 3 | M | 65 | IVB | BM, PB | CT and RT (no details) | PD | 15/D | D2 | + | + | — | + | — | + | Diffuse/typical |
| 4 | M | 56 | IVA | BM, CNS | CVP, rituximab, fludarabine, RT | PR | 62/D | D2w | + | + | — | + | — | + | Vaguely nodular/typical |
| 5 | F | 76 | NA | BM, PB | NA | NA | NA | D3 | + | + | — | + | — | + | Diffuse/typical |
| 6 | M | 63 | IVB | BM, S, PB, CNS | Chlorambucil, CHOP | CR | 12/D | D3 | + | — | — | + | — | + | Diffuse/blastoid |
| 7 | M | 66 | IVB | BM, CNS | CHVmP-BV | CR | 15/D | D3w/Ew | +w | — | — | — | — | + | Diffuse/blastoid |
| 8 | M | 42 | IVB | BM, CNS | CHOP | CR | 37/D | E | + | — | — | +w | — | + | Diffuse/blastoid |
| Case no. . | Sex . | Age, y . | Ann Arbor stage . | Extranodal sites . | Initial therapy . | Response . | Follow-up, mo/status . | Pathologic features . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marker expression . | Growth pattern/cytology . | ||||||||||||||
| Cyclin . | p27 . | RB1 . | Other reviewed markers . | ||||||||||||
| CD3 . | CD5 . | CD10 . | CD20 . | ||||||||||||
| 1 | F | 43 | IVB | BM, T | CHVmP-BV, CEP, DHAP | PR | 19/D | D1 | +w | + | — | +w | — | + | Vagualy nodular/typical |
| 2 | M | 51 | IVB | BM, S, CNS | CHVmP-BV | PR | 64/D | D1 | + | + | — | + | — | + | Nodular/typical |
| 3 | M | 65 | IVB | BM, PB | CT and RT (no details) | PD | 15/D | D2 | + | + | — | + | — | + | Diffuse/typical |
| 4 | M | 56 | IVA | BM, CNS | CVP, rituximab, fludarabine, RT | PR | 62/D | D2w | + | + | — | + | — | + | Vaguely nodular/typical |
| 5 | F | 76 | NA | BM, PB | NA | NA | NA | D3 | + | + | — | + | — | + | Diffuse/typical |
| 6 | M | 63 | IVB | BM, S, PB, CNS | Chlorambucil, CHOP | CR | 12/D | D3 | + | — | — | + | — | + | Diffuse/blastoid |
| 7 | M | 66 | IVB | BM, CNS | CHVmP-BV | CR | 15/D | D3w/Ew | +w | — | — | — | — | + | Diffuse/blastoid |
| 8 | M | 42 | IVB | BM, CNS | CHOP | CR | 37/D | E | + | — | — | +w | — | + | Diffuse/blastoid |
BM indicates bone marrow; T, tonsil; CHVmP-BV, cyclophosphamide, adriamycine, teniposide, methylprednisolone, bleomycine, vincristine; CEP, CCNU, etopsoide, prednisone; DHAP, cisplatinum, cytarabine, dexamethasone; PR, partial response; D, died; w, weak; S, spleen; CNS, central nervous system; PB, peripheral blood; CT, chemotherapy; RT, radiotherapy; PD, progressive disease; CVP, cyclophosphamide, vincristine, prednisone; NA, not available; CHOP, cyclophosphamide, adriamycine, vincrisitine, prednisone; and CR, complete response.